Kumar Srinivasan
Directeur/Membre du Conseil chez TRANSCENTA HOLDING LIMITED
Fortune : 6 826 $ au 31/05/2024
Postes actifs de Kumar Srinivasan
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| TRANSCENTA HOLDING LIMITED | Directeur/Membre du Conseil | 19/12/2022 | - |
| Independent Dir/Board Member | 19/12/2022 | - | |
Pulmotect, Inc.
 Pulmotect, Inc. BiotechnologyHealth Technology Pulmotect, Inc. develops clinical stage, novel, pathogen-agnostic, inhaled compound for the prevention and early treatment of acute, severe viral and bacterial respiratory infections. It provides safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague). The company was founded by Brenton Scott and Magnus Hook in 2007 and is headquartered in Houston, TX. | Directeur/Membre du Conseil | - | - |
Wugen, Inc.
 Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | Directeur Général | 13/03/2023 | - |
| President | 13/03/2023 | - |
Historique de carrière de Kumar Srinivasan
Anciens postes connus de Kumar Srinivasan
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| TURG POIN | Corporate Officer/Principal | 01/06/2021 | - |
Formation de Kumar Srinivasan
| Case Western Reserve University | Doctorate Degree |
| The University of Chicago Booth School of Business | Masters Business Admin |
| University of Madras | Graduate Degree |
Statistiques
Internationale
| Etats-Unis | 6 |
| Chine | 2 |
| Inde | 2 |
Opérationnelle
| Director/Board Member | 2 |
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 4 |
| Technology Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| TRANSCENTA HOLDING LIMITED | Health Technology |
| Entreprise privées | 3 |
|---|---|
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Pulmotect, Inc.
Pulmotect, Inc. BiotechnologyHealth Technology Pulmotect, Inc. develops clinical stage, novel, pathogen-agnostic, inhaled compound for the prevention and early treatment of acute, severe viral and bacterial respiratory infections. It provides safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague). The company was founded by Brenton Scott and Magnus Hook in 2007 and is headquartered in Houston, TX. | Health Technology |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | Technology Services |
- Bourse
- Insiders
- Kumar Srinivasan
- Expérience
